YRDC and hepatocellular carcinoma: Additionally, due to the inhibition of lenvatinib on YRDC, the expression of YRDC would be lower after lenvatinib treatment in original sensitive HCC cells (Figures 5A,B), and it may be an underlying cause due to which the resistance emerges soon after lenvatinib initial treatment.